Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results

BACKGROUND: Etravirine (ETR), an NNRTI approved for 200 mg BID dosing in conjunction with other antiretrovirals (ARVs), has pharmacokinetic properties which support once-daily dosing. METHODS: In this single arm, open-label study, 79 treatment-naïve HIV-infected adults were assigned to receive ETR 4...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Antivir Ther
Egile Nagusiak: Floris-Moore, Michelle A, Mollan, Katie, Wilkin, Aimee M, Johnson, Marc A, Kashuba, Angela DM, Wohl, David A, Patterson, Kristine B, Francis, Owen, Kronk, Catherine, Eron, Joseph J
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546302/
https://ncbi.nlm.nih.gov/pubmed/26263403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3851/IMP2982
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak